Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 3, 2012, Pages 314-320

  Amoroso, Anthony ^a   Etienne Mesubi, Martine ^a   Edozien, Anthony ^a   Ojoo, Sylvia ^a   Sheneberger, Robert ^a   Obiefune, Michael ^a   Hossain, Mian Bazle ^a   Stafford, Kristen ^a   Redfield, Robert R ^a  

^a INSTITUTE OF HUMAN VIROLOGY   (United States)

Author keywords

baseline CD4; efavirenz; first line regimen; nevirapine; resource limited settings; tenofovir

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PATIENT INFORMATION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEP WISE MULTIPLE REGRESSION; UNSPECIFIED SIDE EFFECT;

ADENINE; ADULT; AGE FACTORS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DEOXYCYTIDINE; DEVELOPING COUNTRIES; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NEVIRAPINE; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84864325696     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31824e5256     Document Type: Article

References (33)

1. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Available at: http://www.who.int/HIV/pub/ mtct/advice/en/. Accessed April 15, 2011.
2. Overview of All Supply Chain Management System (SCMS) Core Formulary Lists. The Supply Chain Management System. Available at: http://scmsweb.pfscm. org/scms/ecatalog. Accessed April 8, 2011.
3. Chi BH, Mwango A, Giganti M, et al. Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune Defic Syndr. 2010;54:63-70.
4. Etienne-Mesubi M, Amoroso A, Edozien A, et al. A global clinical comparison of TDF+3TC+NVP vs. TDF+ 3TC+EFV in resource constrained populations abstract Z-167. Paper presented at the 18th Annual Conference on Retroviruses and Opportunistic Infections; February 2, 2011; Boston, MA.
5. Amoroso A, Gilliam BL, Talwani R, et al. Viral load decay in antiretroviral-naive patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapine. HIV Clin Trials. 2009;10:320-323.
6. Droste JA, Kearney BP, Hekster YA, et al. Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;41:37-43.
7. Spaulding A, Rutherford GW, Siegfried N. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst Rev. 2010;6:CD008740.
8. Gathe J, Andrade-Villanueva J, Santiago S, et al. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediaterelease twice-daily in treatment-naive HIV-1-infected patients. Antivir Ther. 2011;16:759-769.
9. Weberschock T, Gholam P, Hueter E, et al. Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week Prospective Multicenter Study (TENOR-Trial). Eur J Med Res. 2009;14:516-519.
10. Smith DE, Chan DJ, Maruszak H, et al. Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects. Int J STD AIDS. 2011;22:228-230.
11. Soriano V, Arastéh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther. 2011;16:339-348.
12. Dejesus E, Mills A, Bhatti L, et al. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients. Int J Clin Pract. 2011;65:1240-1249.
13. Labarga P, Medrano J, Seclen E, et al. Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients. AIDS. 2010;24: 777-779.
14. Redfield R, Morrow J. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine. Clin Infect Dis. 2008; 47:984.
15. Davis C, Gilliam B, Amoroso A, et al. Lack of pharmacokinetic interaction of tenofovir (TDF) and emtricitabine (FTC) on nevirapine (NVP) abstract P4.1/03. Paper presented at 11th European AIDS Conference (EACS); October 25, 2007; Madrid, Spain.
16. Tang M, Kanki P, Shafer R. Virological efficacy of the four tenofovircontaining WHO-recommended regimens for initial antiretroviral therapy abstract WEPDB0103. Paper presented at 6th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; July 20, 2011; Rome, Italy.
17. Lapadula G, Costarelli S, Quiros-Roldan E, et al. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients. Clin Infect Dis. 2008;46:1127-1129.
18. Rey D, Hoen B, Chavanet P, et al. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother. 2009;63:380-388.
19. Scarsi K, Darin K, Rawizza H. TDF/3TC/NVP is inferior to AZT/3TC/NVP in a large ART program in Nigeria abstract PE0115. Paper presented at the 18th International AIDS Conference; July 19, 2010; Vienna, Austria.
20. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. Department of Health and Human Services. Available at http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed December 5, 2011.
21. Keiser P, Nassar N, White C, et al. Comparison of nevirapine and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study. HIV Clin Trials. 2002;3:296-303.
22. Bannister WP, Ruiz L, Cozzi-Lepri A, et al. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS. 2008;22:367-376.
23. Gaytan A, de la Garza E, Garcia MC, et al. Nevirapine or efavirenz in combination with two nucleoside analogues in HIV infected antiretroviral naïve patients. Med Intern Mex. 2004;20:24.
24. Nuñez M, Soriano V, Martin-Carbonero L, et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials. 2002;3:186-194.
25. Nachega JB, Hislop M, Dowdy DW, et al. Efavirenz versus nevirapinebased initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS. 2008;22:2117-2125.
26. van den Berg-Wolf M, Hullsiek KH, Peng G, et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials. 2008;9: 324-336.
27. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253-1263.
28. Campbell T, Smeaton L, Kumarasamy N, et al. Efficacy and safety of EFV with either co-formulated 3TC/ZDV OR FTC/TDF for initial treatment of HIV-1 infected men and women in diverse multinational settings: ACTG PEARLS Study abstract 149LB. Paper presented at the 18th Annual Conference on Retroviruses and Opportunistic Infections, March 2, 2011, Boston, MA.
29. Etienne M, Aina O, Mesubi O, et al. Provider assessment of patient adherence: a poor predictor of viral suppression in resource limited settings abstract WEPEB100. Paper presented at the 4th IAS Conference; 2007; Sydney, Australia.
30. Pozniak AL, Gallant JE, DeJesus E. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535-540.
31. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir ImmuneDefic Syndr. 2008;47:74-78.
32. Havlir VD, Koelsch KK, Strain CM. Predictors of residual viremia in HIV infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis. 2005;191: 1164-1168.
33. Haïm-Boukobza S, Morand-Joubert L, Flandre P, et al. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. AIDS. 2011;25:341-344.